Daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection among gay men at high risk of becoming HIV positive, according to an open-label randomized trial designed to assess the real-life effectiveness of PrEP. Concerns had been raised that individuals taking PrEP would engage in riskier sexual practices, counteracting the benefits of PrEP. However, the investigators suggest these findings provide evidence that the effectiveness of PrEP would not be compromised by behavioral “risk compensation” (McCormack S et al. Lancet. doi:10.1016/S0140-6736(15)00056-2 [published online September 9, 2015]).
Slomski A. PrEP Reduces Incidence of HIV in Clinical Settings. JAMA. 2015;314(16):1684. doi:10.1001/jama.2015.13424